SATO America的动态

BCBN Feed: Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod? 5 Automated Insulin Delivery System is Superior to Pump Therapy https://lnkd.in/dqfEBCEw ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated... ... [...]

Today, insulin-requiring people with #diabetes must invest significant time to learn how to manage their #insulintherapy, cover high out-of-pocket expenses, and operate complicated “advanced” pump systems. With Modular Medical's (NASDAQ: MODD) #MODD1, a slow basal dose occurs and the delivery of a bolus is with the click of a button. No more uncomfortable #injections. No more hassle with complicated system.

No prescription? No problem! Abbott Continous Glucose Monitoring (CGM) systems are now over-the-counter products. A few days back, the USFDA approved two new over-the-counter continuous glucose monitors (CGMs) from Abbott. This is a game-changer for millions of Americans living with diabetes. U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems, – Lingo? and Libre Rio?, which are based on Abbott's world-leading?continuous glucose monitoring technology .i.e. FreeStyle Libre Sensing Technology. ? Why this matters : 1) Increased Accessibility 2) Empowering Self Management 3) Potential Cost Saving ? Advantages of this Technology are : 1) No blood sample required. 2) Doesn’t need a finger stick. 3) Painless sensor application process. 4) Convenient for travel, work. This approval marks a significant step forward in diabetes care, making advanced glucose monitoring technology more accessible to those who need it. It highlights the dynamic innovation in the medical device industry and underscores the FDA's commitment to patient-centric healthcare solutions. #Diabetescare #MedicalDevices #HealthcareInnovation #AbbottLabs

Dexcom Earns FDA Clearance for OTC Glucose Biosensor in the U.S. - HIT Consultant #Dexcom FDA Clearance for OTC Glucose Biosensor #FDA Clearance for Over-The-Counter Use Dexcom has received FDA clearance for an over-the-counter glucose biosensor, allowing individuals to monitor their glucose levels without a prescription. This approval marks a significant milestone in diabetes management and empowers patients to take control of their health. #Continuous Glucose Monitoring Technology The Dexcom OTC biosensor utilizes cutting-edge continuous glucose monitoring (CGM) technology to provide real-time glucose readings. This technology offers greater accuracy and convenience compared to traditional glucose monitoring methods, making it easier for patients to track their glucose levels throughout the day. #Improved Diabetes Management By enabling individuals to monitor their glucose levels more easily and conveniently, the ai.mediformatica.com #dexcom #glucose #diabetes #continuousglucosemonitoring #glucosemonitoring #prescription #type2diabetes #insulin #technology #acce #this #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4bXwsMR)

Disposable Sterile Insulin Syringes Market Size, Share, Trends, and Analysis: 2024-2030 https://lnkd.in/emGsc4ep #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Valuable Metrics and Improving Adherence in Patients With ASCVD: Expert perspectives on metrics that pharmacists can track to quantify adherence rate improvement, treatment intensification, and cholesterol level optimization over time. #finance #pharmacy #lifesciences

Hitting a weight loss wall? Semaglutide Injectables can help you push past it. This innovative treatment supports your body’s natural weight loss mechanisms, making those tough-to-shed pounds easier to lose. Learn more by visiting the link in our bio. #WeightLossJourney #SemaglutideSuccess #HealthyTransformation #VIOSCompoundingPharmacy

Establish?a?Profitable?Glucose Saline Manufacturing?Plant?Setup?|?Syndicated?Analytics Glucose saline, also known as dextrose saline, refers to a sterile solution used for medical purposes that combines #sodium chloride and glucose in water. It is utilized for intravenous hydration and electrolyte balancing in patients. Glucose saline is available in various concentrations and includes purified water, sodium chloride, and dextrose to ensure compatibility with the body’s natural fluids. It finds applications in various #medical settings, including rehydration therapy, nutrient and electrolyte replenishment, hypoglycemia, drug delivery, intravenous therapy, fluid loss replacement, post-operative care (POC), dehydration, diluting medications, and pediatric care. Read more at: https://bit.ly/3v8CSYK #GlucoseSaline #syndicatedanalytics #rawmaterials #manufacturingPlant #projectreport #plantcost #costanalysis #businessplan #plantsetup

Troches are square-shaped solid dosages designed to dissolve slowly in the mouth, utilizing oral mucosa absorption. This method, known as buccal administration, ensures that the medication avoids metabolism in the gastrointestinal tract and is instead directly absorbed into the bloodstream. Learn more about troche-based formulations with sildenafil or tadalafil on our website: https://lnkd.in/et5Pe3Jx #medicationtherapymanagement #medicationmanagement #medicationadherence #medicationsafety #medication #health #healthcareproducts #healthcare #healthandwellness #treatment #treatmentplan #patient #patientcare #patientsafety #patientexperience #healthprofessionals #healthcareproviders #compound #compoundpharmacy #compoundtreatment #pharmacy #pharmaceuticalindustry #pharmaceuticalmanufacturing #erectiledysfunction #troche

??Medicine shortage update – Substitution allowed to address shortage of Ryzodeg 70/30 FlexTouch insulin?? We are aware of the unavailability of Ryzodeg 70/30 FlexTouch insulin prefilled pens. Novo Nordisk, the supplier of Ryzodeg in Australia, has notified us of its decision to discontinue marketing Ryzodeg 70/30 FlexTouch insulin prefilled pens from 1 February 2025. Ryzodeg FlexTouch has been in short supply since 30 June 2023. To help manage the shortage and upcoming discontinuation, we have made a Serious Scarcity Substitution Instrument. This means that pharmacists can give patients Ryzodeg 70/30 Penfill cartridges instead of Ryzodeg 70/30 FlexTouch prefilled pens under certain conditions. Both products contain the same medicine, at the same strength, have the same storage requirements, and are administered by injection under the skin (subcutaneous injection). However, the device used to administer the medicine is different. For detailed information, visit our website: https://lnkd.in/gwfHwC-J